AL-ADTRAN
25.3.2024 14:01:34 CET | Business Wire | Press release
Adtran and Vertilas today announced the industry’s first 100Gbit/s PAM4 single-mode vertical-cavity surface-emitting laser (VCSEL) technology with capabilities up to 1.6Tbit/s. On display at this week’s OFC, it sets new standards for low power consumption in optical engines and modules, with up to 80% reduction in power on the transmit optics compared to conventional solutions. Tailored specifically for the rigorous demands of intra-data center operations and AI/ML workloads, Adtran’s latest offering achieves unprecedented efficiency, consuming less than 2pJ/bit, including the laser driver. This significantly undercuts current industry standards, including those cited by co-packaged optics. The advancement is set to extend the capabilities of Adtran’s MicroMux™ family of small-form-factor pluggable transceivers. A major step towards meeting the needs of the rapidly expanding generative AI application market, Adtran’s latest innovation addresses the growing demand for robust, high-capacity and environmentally friendly data processing solutions.
“As the importance of data volume and speed escalates, the demand for increased bandwidth and enhanced energy efficiency accelerates. Our introduction of the market’s first 100Gbit/s PAM4 single-mode VCSEL technology, scalable to 1.6Tbit/s, epitomizes our proactive approach to tackling these emerging requirements. By pushing the limits of speed and significantly reducing power consumption, we’re creating tomorrow’s benchmarks,” said Ross Saunders, GM of optical engines at Adtran. “Our new technology promises to significantly improve intra-data center connectivity and AI application efficiencies, merging high performance with long-term sustainability. As we prepare for the leap towards 800Gbit/s and 1.6Tbit/s applications, we’re enhancing the foundations of efficient, high-capacity data ecosystems worldwide.”
Building on the success of Adtran’s MicroMux™ family, the new VCSEL technology leverages a short-cavity single-mode design and is based on indium phosphide semiconductor material. This enables it to operate across both O-band and C-band wavelengths, delivering 100Gbit/s per channel. By stacking multiple single-mode lasers into arrays, this approach achieves throughput of 800Gbit/s and 1.6Tbit/s, ensuring superior performance with a significant reduction in power consumption and costs. This enhanced energy efficiency presents a major advantage for IP router and Ethernet switch faceplate density. What’s more, its versatility extends to supporting a wide array of applications from DR4/8/16 to various FR4 links within optical engines, all while maintaining power consumption below 200mW per lane.
“As applications such as generative AI proliferate and enterprises expand their AI clusters, the need for advanced optical interconnects capable of supporting Terabit connectivity has reached a critical juncture. Our 100Gbit/s PAM4 single-mode VCSEL technology meets this challenge head-on. It enables energy efficiency and the capacity for higher-density deployments while at the same time addressing manufacturing, testing and assembly costs,” commented Christoph Glingener, CTO of Adtran. “This technology supports throughput of up to 800Gbit/s and 1.6Tbit/s, significantly reducing operational expenses while enhancing network capabilities. Our approach underscores a commitment to delivering sustainable, high-capacity networking solutions that break through existing barriers, readying networks for the next wave of AI infrastructure development.”
Demos of Adtran’s new VCSEL technology are available at this week’s OFC on request.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240322173283/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom